What is HC Wainwright’s Estimate for BioNTech Q2 Earnings?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of BioNTech in a note issued to investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will earn $3.78 per share for the quarter, up from their previous estimate of $3.72. HC Wainwright has a “Buy” rating and a $138.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

Several other research firms also recently commented on BNTX. JPMorgan Chase & Co. reduced their price objective on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research note on Thursday, May 22nd. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th. Leerink Partners set a $112.00 price target on BioNTech in a report on Monday, June 2nd. Truist Financial reiterated a “buy” rating and set a $155.00 price target (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Finally, The Goldman Sachs Group assumed coverage on BioNTech in a report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $137.86.

BioNTech Stock Up 1.3%

NASDAQ BNTX opened at $106.14 on Thursday. The business has a fifty day moving average price of $102.63 and a 200 day moving average price of $107.30. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The company has a market cap of $25.51 billion, a P/E ratio of -31.22 and a beta of 1.29.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise purchased a new stake in BioNTech in the 1st quarter valued at about $36,000. Jones Financial Companies Lllp raised its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares during the period. Banque Transatlantique SA purchased a new stake in BioNTech in the 1st quarter valued at about $80,000. Quintet Private Bank Europe S.A. raised its holdings in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the period. Finally, Allianz SE purchased a new stake in BioNTech in the 4th quarter valued at about $90,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.